Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

61.51
+1.071.77%
Post-market: 61.510.00000.00%19:54 EDT
Volume:1.16M
Turnover:70.74M
Market Cap:5.97B
PE:26.31
High:62.47
Open:60.59
Low:60.18
Close:60.44
Loading ...

Sarepta weakness ‘compelling’ buying opportunity, says Mizuho

TIPRANKS
·
19 Mar

Sarepta Therapeutics’ Elevidys: Maintaining a Buy Rating Amid Safety Concerns and Low Adverse Effect Incidence

TIPRANKS
·
19 Mar

Sarepta Therapeutics Is Maintained at Hold by Deutsche Bank

Dow Jones
·
19 Mar

Post-Bell | Wall Street Ends Lower; Tesla Sinks 5%; Nvidia Falls 3%; Meta and Palantir Drop 4%; Tiger Brokers Soars 22%

Tiger Newspress
·
19 Mar

Sarepta Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
19 Mar

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today

StockStory
·
18 Mar

Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley

TIPRANKS
·
18 Mar

Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink

TIPRANKS
·
18 Mar

Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys

TIPRANKS
·
18 Mar

Sarepta shares to dislocate from fundamentals after patient death, says JPMorgan

TIPRANKS
·
18 Mar

Sarepta Selloff Seen as Overdone -- Market Talk

Dow Jones
·
18 Mar

Sarepta Therapeutics Shares Down 24.3%; Co Reports Patient Death Following Treatment With Its Gene Therapy

THOMSON REUTERS
·
18 Mar

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Benzinga
·
18 Mar

Sarepta Therapeutics Price Target Maintained With a $163.00/Share by Cantor Fitzgerald

Dow Jones
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics

Reuters
·
18 Mar

Sarepta Therapeutics stock falls after DMM patient dies of liver failure

Dow Jones
·
18 Mar

Sarepta Therapeutics Says Patient Who Passed Away After Treatment With Elevidys Was 16 Years Old, Received Treatment in December - Statement

THOMSON REUTERS
·
18 Mar

Sarepta falls after notifying of patient death following treatment with Elevidys

TIPRANKS
·
18 Mar

Cantor Fitzgerald Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
18 Mar

Sarepta Therapeutics Shares Down 26% Premarket; Co Reports Patient Death Following Treatment With Its Gene Therapy

THOMSON REUTERS
·
18 Mar